Abequolixron

Generic Name: Abequolixron

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₃₄H_₃₃ClF_₃NO_₃

CAS Number: 610318-54-2

Unique Ingredient Identifier: Q26B92650V

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Abequolixron (RGX-104) and Durvalumab in Lung Cancer

Phase 1

Recruiting

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Durvalumab
Drug: Carboplatin
Drug: Abequolixron
Drug: Abraxane
Drug: Pemetrexed

First Posted Date: 2023-06-22

Last Posted Date: 2024-08-19

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 24

Registration Number: NCT05911308

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy